Education
About Us
Working with TipRanks
Follow Us
Zhaoke Ophthalmology Ltd. (HK:6622)
:6622
6622 Stock Chart & Stats
HK$3.17
HK$0.01(0.78%)
At close: 4:00 PM EST
HK$3.17
HK$0.01(0.78%)
Day’s Range― - ―
52-Week RangeHK$1.30 - HK$4.60
Previous CloseN/A
Volume310.50K
Average Volume (3M)1.25M
Market Cap
HK$1.90B
Enterprise ValueHK$871.08M
Total Cash (Recent Filing)HK$1.05B
Total Debt (Recent Filing)HK$271.40M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding547,970,030
10 Day Avg. Volume1,172,850
30 Day Avg. Volume1,251,992
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.32
Price to Sales (P/S)8.88
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA strong equity base and low financial leverage provide durable financial stability, increasing the company's ability to fund multi-year R&D and commercialization cycles without heavy interest burdens. This reduces bankruptcy risk and supports strategic investment flexibility.
Top-line MomentumSustained revenue growth signals growing market adoption of its ophthalmology products and services, which underpins longer-term scale economics. Persistent top-line expansion can support future margin improvement as fixed costs are absorbed and commercial infrastructure scales.
Focused Ophthalmology FranchiseA specialized ophthalmology focus creates deep domain expertise, higher barriers to entry, and product-tailored R&D pathways. This concentration supports differentiated pipelines, strategic partnerships, and durable competitive positioning in a niche clinical market.
Bears Say
Persistent UnprofitabilityOngoing negative profitability erodes retained earnings and limits internal funding for trials and commercialization. Over time, sustained operating losses increase reliance on external capital, heighten dilution risk, and constrain ability to demonstrate consistent free-cash-flow generation.
Weak Cash GenerationNegative operating and free cash flows indicate difficulty converting revenue into liquid resources, threatening runway for clinical programs and commercial expansion. Structurally weak cash conversion raises dependence on financing and can limit strategic optionality.
Limited Investor TransparencyAbsence of earnings calls or notable corporate events reduces visibility into management's guidance, capital plans, and execution priorities. Over months this limits investors' ability to assess progress on clinical, commercial, and financing milestones, increasing uncertainty.
Zhaoke Ophthalmology Ltd. News
6622 FAQ
What was Zhaoke Ophthalmology Ltd.’s price range in the past 12 months?
Zhaoke Ophthalmology Ltd. lowest stock price was HK$1.30 and its highest was HK$4.60 in the past 12 months.
What is Zhaoke Ophthalmology Ltd.’s market cap?
Zhaoke Ophthalmology Ltd.’s market cap is HK$1.90B.
When is Zhaoke Ophthalmology Ltd.’s upcoming earnings report date?
Zhaoke Ophthalmology Ltd.’s upcoming earnings report date is Mar 30, 2026 which is in 36 days.
How were Zhaoke Ophthalmology Ltd.’s earnings last quarter?
Zhaoke Ophthalmology Ltd. released its earnings results on Aug 28, 2025. The company reported -HK$0.238 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.238.
Is Zhaoke Ophthalmology Ltd. overvalued?
According to Wall Street analysts Zhaoke Ophthalmology Ltd.’s price is currently Overvalued.
Does Zhaoke Ophthalmology Ltd. pay dividends?
Zhaoke Ophthalmology Ltd. does not currently pay dividends.
What is Zhaoke Ophthalmology Ltd.’s EPS estimate?
Zhaoke Ophthalmology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhaoke Ophthalmology Ltd. have?
Zhaoke Ophthalmology Ltd. has 547,970,030 shares outstanding.
What happened to Zhaoke Ophthalmology Ltd.’s price movement after its last earnings report?
Zhaoke Ophthalmology Ltd. reported an EPS of -HK$0.238 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.05%.
Which hedge fund is a major shareholder of Zhaoke Ophthalmology Ltd.?
Currently, no hedge funds are holding shares in HK:6622
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhaoke Ophthalmology Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.41%
12-Months-Change
Fundamentals
Return on Equity
-14.84%
Trailing 12-Months
Asset Growth
-11.56%
Trailing 12-Months
Company Description
Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
Technical Analysis
Ocumension Therapeutics
―
TOT BIOPHARM International Co. Ltd.
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
Immunotech Biopharm Ltd
―